Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.

Alice IndiniLorenza Di GuardoCarolina CimminielloMichele PrisciandaroGiovanni RandonFilippo De BraudMichele Del Vecchio

Published in: Journal of cancer research and clinical oncology (2018)

Our study underlines the association between irAEs and survival outcomes from anti-PD1 therapy. Careful management of treatment-related toxicity can lead to achieve maximum clinical benefit from this therapy.

Keyphrases

patients undergoing
oxidative stress
free survival
stem cells
combination therapy
bone marrow
cell therapy